Success Metrics

Completion Rate

0%(0/1)

Active Trials

3(75%)

Terminated

1(25%)

Phase Distribution

Ph not_applicable

25%

Ph phase_2

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 2Efficacy & side effects

2(66.7%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Terminated(1)

Detailed Status

Recruiting3

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 2

Trials by Phase

Phase 22 (66.7%)

N/A1 (33.3%)

Trials by Status

terminated125%

recruiting375%

Recent Activity

3 active trials

Showing 4 of 4

recruitingphase_2

Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer

NCT07218601

recruiting

Study to Understand Novel Biomarkers in Researching Dementia

NCT06547099

recruitingnot_applicable

PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer

NCT02732171

terminatedphase_2

Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)

NCT04267120

Clinical Trials (4)

Showing 4 of 4 trials

NCT07218601Phase 2

Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer

Recruiting

NCT06547099

Study to Understand Novel Biomarkers in Researching Dementia

Recruiting

NCT02732171Not Applicable

PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer

Recruiting

NCT04267120Phase 2

Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)

Terminated

All 4 trials loaded

Drug Details

Intervention Type: OTHER
Total Trials: 4